Focus: MBX Biosciences is a publicly traded biotech company focused on hormone analogues for rare endocrine diseases, headquartered in Carmel, Indiana. The company operates in a specialized niche within endocrinology and rare diseases with a pre-revenue or early-stage commercial model.
Profile data last refreshed 56m ago · AI intelligence enriched 2w ago
Stable — net +2 jobs in 30d
7 added, 5 removed. Backfill posture.
MBX is a high-risk, high-potential-reward play best suited for biotech professionals comfortable with pre-revenue stage science, rare disease focus, and meaningful equity upside contingent on Phase 2→3 advancement.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for MBX Biosciences
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MBX Biosciences's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio - The Manila Times
MBX Biosciences to Host In-Person and Virtual Obesity Day on May 11, 2026 to Discuss Expanding Obesity Portfolio The Manila Times
Aaron Wealth Advisors Increases Stake in MBX Biosciences, Betting on Precision Peptide Therapies for Rare Diseases - NAI500
Aaron Wealth Advisors Increases Stake in MBX Biosciences, Betting on Precision Peptide Therapies for Rare Diseases NAI500
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? - simplywall.st
MBX Biosciences (MBX) Is Up 16.6% After Analyst Initiation And Leadership Award News Has The Bull Case Changed? simplywall.st
Assessing MBX Biosciences (MBX) Valuation After CEO Share Purchase And Phase 3 Hypoparathyroidism Plans - simplywall.st
Assessing MBX Biosciences (MBX) Valuation After CEO Share Purchase And Phase 3 Hypoparathyroidism Plans simplywall.st
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: MBX Biosciences, Inc. (MBX) and REPRO-MED Systems (KRMD) The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD) - The Globe and Mail
Analysts Are Bullish on Top Healthcare Stocks: MBX Biosciences, Inc. (MBX), REPRO-MED Systems (KRMD) The Globe and Mail
Showing 6 of 10 news items
Based on last 4 crawl cycles
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo